Introduction
Surgical mitral valve replacement has been the mainstay treatment for
degenerated bioprosthesis. However, the transcatheter valve-in-valve
procedure is increasingly recognized as an alternative treatment in
selected patients. 1 Moreover, percutaneous valve
technology continues to evolve, making these valves available for use in
a broader population. 1 In 2017, the American Heart
Association/American College of Cardiology updated its guidelines for
management of patients with valvular heart disease, changing the word
“reoperation” to “reintervention” to account for transcatheter
valves. 2 However, although bioprosthetic valves have
shown good reliability in older patients, they degenerate more quickly
in younger patients, presumably because of the increased contractility
and valve stress among those with increased activity.3 We present a case involving a 13-year old female who
received a transcatheter valve for degenerated mitral bioprosthesis with
30 months of follow up. To the best of our knowledge, this is the
youngest patient to undergo this procedure.